Enzo Biochem Launch of Test for Measuring Risk of Colorectal Cancer Underscores Growing Role of Molecular Diagnostics

April 2012
Biomedical Market Newsletter;4/14/2012, Vol. 21, p1
The article informs that Enzo Biochem Inc. has launched the ColonSentry test for assessing a patient's risk of having colorectal cancer. ColonSentry is a first of its kind blood-based risk stratification test for colorectal cancer. The test utilizes RNA to measure the level of expression of seven specific genes by using only a small sample of blood.


Related Articles

  • PD-0023 VALIDATION STUDY OF A BLOOD-BASED GENE EXPRESSION SIGNATURE FOR COLORECTAL CANCER DETECTION. Xu, Q.; Ye, X.; Wu, F.; Meng, X. // Annals of Oncology;Jun2014, Vol. 25 Issue suppl_2, pii13 

    No abstract available.

  • High-throughput sequencing to identify miRNA biomarkers in colorectal cancer patients. YAN SUN; LIN WANG; SHENG-CHAO GUO; XIAO-BING WU; XUE-HU XU // Oncology Letters;2014, Vol. 8 Issue 2, p711 

    The altered expression of microRNAs (miRNAs) is associated with a number of cancer types. The study of the association between the miRNA profile and cancer may be useful to identify potential biomarkers of certain types of cancer. In the present study, 19 miRNAs were identified by...

  • Blood-Based Tests for Colorectal Cancer Screening: Do They Threaten the Survival of the FIT Test? Bresalier, Robert; Kopetz, Scott; Brenner, Dean // Digestive Diseases & Sciences;Mar2015, Vol. 60 Issue 3, p664 

    Colorectal cancer is the second leading cause of cancer death in industrialized nations, accounting for 10 % of the total cancer burden with an individual lifetime risk of ~6 % in the USA (Siegel et al. in CA Cancer J Clin 62:9-29, , American Cancer Society in Colorectal cancer facts and figures...

  • Multi-Target Stool DNA Test: A New High Bar for Noninvasive Screening. Ahlquist, David // Digestive Diseases & Sciences;Mar2015, Vol. 60 Issue 3, p623 

    Stool DNA testing has evolved into what is now a highly accurate and well-validated test for the screen detection of colorectal neoplasia. An optimized and automated multi-target stool DNA test (MT-sDNA) has achieved the same high point-sensitivities as reported for colonoscopy and significantly...

  • Nuclear-enriched abundant transcript 1 as a diagnostic and prognostic biomarker in colorectal cancer. Yuchen Wu; Li Yang; Jiang Zhao; Cong Li; Jia Nie; Fangqi Liu; Changhua Zhuo; Yaxin Zheng; Bin Li; Zhimin Wang; Ye Xu // Molecular Cancer;11/9/2015, Vol. 14 Issue 1, p1 

    Background: High expression of the long non-coding RNA nuclear-enriched abundant transcript 1 (NEAT1) in whole blood has been reported in colorectal cancer patients; however, its' clinical significance and origin are unclear. We evaluated the diagnostic and prognostic value, and origin of whole...

  • Serum expression of miRNA-103, a potential diagnostic and prognostic biomarker for colorectal cancer. Liangang Mao; Weiyun Feng; Yongming Yu; Xiaomin Xu // International Journal of Clinical & Experimental Medicine;2016, Vol. 9 Issue 7, p14212 

    Objectives: To investigate the potential clinical utility of miR-103 as noninvasive diagnostic, prognostic and metastasis-predictive biomarker in patients with colorectal cancer (CRC). Methods: 108 patients scheduled to undergo surgery in Department of Gastrointestinal Surgery, Ningbo NO. 2...

  • DNA copy number alterations, gene expression changes and disease-free survival in patients with colorectal cancer: a 10 year follow-up. Bigagli, Elisabetta; Filippo, Carlotta; Castagnini, Cinzia; Toti, Simona; Acquadro, Francesco; Giudici, Francesco; Fazi, Marilena; Dolara, Piero; Messerini, Luca; Tonelli, Francesco; Luceri, Cristina // Cellular Oncology (2211-3428);Dec2016, Vol. 39 Issue 6, p545 

    Background: DNA copy number alterations (CNAs) and gene expression changes have amply been encountered in colorectal cancers (CRCs), but the extent at which CNAs affect gene expression, as well as their relevance for tumor development, are still poorly defined. Here we aimed at assessing the...

  • What an abnormal FIT result really means. Telford, Jennifer J. // British Columbia Medical Journal;Mar2014, Vol. 56 Issue 2, p97 

    The article discusses British Columbia's Colon Screening Program that was introduced in November 2013 and offers colorectal cancer screening to asymptomatic patients aging 50-74 through the fecal immunochemical test.

  • Correlation study of Bcl-2, B7-H1, EGFR, VEGF and colorectal cancer. Xiao-Feng Li; Xian-Feng Liu; Yong-Yan Yang; Ai-Yong Liu; Mei-Yun Zhang; Xue-Feng Bai; Hui Gao; Xiao-Guang Guo // American Journal of Cancer Research;2015, Vol. 5 Issue 7, p2277 

    Objective: To analyze the expressions of Bcl-2, B7-H1, EGFR and VEGF in colorectal cancer for the further investigation of their correlations with the clinical pathological features of colorectal cancer. Method: Fresh colorectal cancer tissues and the expressions of Bcl-2, B7-H1, VEGF and EGFR...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics